Masimo Corp (MASI) FinancialsMASIMasimo Corp

Masimo Corp (MASI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Healthcare, accounting for 99.8% of total sales, equivalent to $402.60M. Another important revenue stream is nonhealthcare. Understanding this composition is critical for investors evaluating how MASI navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Masimo Corp maintains a gross margin of 62.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.18%, while the net margin is 13.95%. These profitability ratios, combined with a Return on Equity (ROE) of 24.99%, provide a clear picture of how effectively MASI converts its operational activities into shareholder value.

In the context of the broader market, MASI competes directly with industry leaders such as SNN and BAX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, MASI's gross margin of 62.14% stands against SNN's 70.91% and BAX's 35.41%. Such benchmarking helps identify whether Masimo Corp is trading at a premium or discount relative to its financial performance.

No usable financial snapshot was provided, so there is no reliable latest-quarter revenue or earnings assessment available here. Based on the data given, the current investment case is being driven almost entirely by the pending acquisition rather than operating fundamentals.